Skip to main content

RT @uptoTate: Tildrakizumab (TIL), anti–IL-23p19 monoclonal ab, superior to PBO in phase 2b trial results in PsA. https://t.co/i0vIEHD4hx #…

Social Author Name
Dr. Rachel Tate
Tweet Content
Tildrakizumab (TIL), anti–IL-23p19 monoclonal ab, superior to PBO in phase 2b trial results in PsA. https://t.co/i0vIEHD4hx #ACR19 @RheumNow abs#2878 https://t.co/OmlhZfGdJi
Show on Archive Page
On
Display in Search Results
On
×